| Summary: | 碩士 === 高雄醫學大學 === 生物化學研究所碩士班 === 93 === Renal-cell carcinoma (RCC) is a very difficult tumor to treat, and response rates to biological therapies are less than 20%. The identification of various molecular and cellular markers has led to the development of novel therapies. We first used the microarray technology to screen the two different expression between RCC tumor sites and normal sites genes — BRAK/CXCL14 and RhoA, and then detected the expression of BRAK/CXCL14 and RhoA by RT-PCR, real-time PCR, Western blotting and immunohistochemistry. Compared with normal sites, our results showed that in the RCC tumor sites of 36 patients, BRAK/CXCL14 was down-regulated in gene and protein level 72.22% and 63.89%, respectively; in cell lines study, RCC cell lines (ACHN, A498, 769-P, 786-O) also had lower expression compared with normal proximal tubule cell line (HK-2). RhoA was up-regulated in gene and protein level 58.33% and 50.00%, respectively; RCC cell lines (ACHN, 769-P, 786-O) also had higher expression compared with HK-2. However, the function of these two genes still need to be further investigated. We expect that BRAK/CXCL14 and RhoA would play an important role in RCC carcinogenesis, and we hope to expand its application in the clinical medicine in the future.
|
|---|
